A|B|C|D|E|F|G|H|I|J|K|L|M|N|O|P|Q|R|S|T|U|V|W|X|Y|Z|ALL

  检 索： 期刊名称 ISSN         高级检索

期刊名称：JOURNAL OF ANTIBIOTICS ISSN： 0021-8820 版本： SCI-CDE 出版频率： Monthly 出版社： JAPAN ANTIBIOT RES ASSN, 2 20 8 KAMIOSAKI, SHINAGAWA KU, TOKYO, JAPAN, 141 期刊网址： http://www.antibiotics.or.jp/journal/ja-top.htm 影响因子： 1.272(2008) 主题范畴： MICROBIOLOGY;    BIOTECHNOLOGY & APPLIED MICROBIOLOGY;    PHARMACOLOGY & PHARMACY;    IMMUNOLOGY 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal The Journal of Antibiotics is a monthly international journal devoted to the publication of research on antibiotics and other types of microbial products. The Journal will publish microbiological, biochemical, chemical and pharmacological studies but not those involving human therapy. Reports on recently discovered antibiotics and bioactive microbial products are especially encouraged. Paper must be in English and are accepted from any country with the understanding that the work described is not being submitted for publication elsewhere. Instructions to Authors Editorial Policy Submission of Manuscripts Preparation of Manuscripts Report Style Nomenclature and Units Nomenclature of Microorganisms Descriptions of Actinomycetes Genetic Nomenclature Chemical and Biochemical Nomenclature Numerical Description and Units Abbreviation Description of Physico-chemical Properties Description of Isotopically Labeled Compounds Proof and Reprints Correction Copyright Crystal Data Form The format of the journal is 21.1 cm width and 29.6 cm length, and all pages, including those containing tables, figures and schemes, are printed in the same orientation (lengthwise or portrait) in a two-column format. Manuscripts should be submitted in triplicate directly to: The Editorial Office of the Journal of Antibiotics Japan Antibiotics Research Association 2-20-8 Kamiosaki, Shinagawa-ku, Tokyo 141-0021, Japan The following four types of papers are acceptable for publication: Original Articles: Reports of high scientific quality and originality that are of interest to the wide and diverse readership of the Journal. Manuscripts should include an abstract or summary, and appropriate experimental details to support the conclusions. The normal length should be five printed pages or less and this should normally not include more than four tables and two illustrations. Notes and Communications to the Editor: Notes are for short experimental reports of more limited scope than Original Articles. Communications to the Editor are for the preliminary reports of unusual urgency, significance and interest, whose subjects may be republished in expanded form. Experimental details are not required in Communications to the Editor, but a general outline of experimental methods should be included. The normal length should be two printed pages or less and this should normally not include more than two tables and one illustration. Review Articles: Critical reviews on subjects related to antibiotics and other microbial products are invited. The length of a review article will depend on the subject. Authors willing to submit review articles should first contact the Managing Editor concerning the suitability of the topic under consideration. For papers longer than the normal length, an excess page charge (亸20,000 or equivalent US dollars per printed page) will be assessed the authors. For extra usage of tables and illustrations, an excess charge (亸2,500 - 5,000 per piece, depending on size and complexity) will be assessed the authors. Inquiries: Tel: +81-3-3491-0181, Fax: +81-3-3491-0179 e-mail address: journal@antibiotics.or.jp ( Submission of manuscripts by e-mail will not be accepted. )   Editorial Board EMERITUS MEMBER T. Aoyagi Tokyo, Japan S. Nakamura Hiroshima, Japan F. M. Arcamone Bologna, Italy K. Nitta Tokyo, Japan W. E. Brown Lawrenceville, U.S.A. Y. Okami Tokyo, Japan J. W. Corcoran Chicago, U.S.A. N. Otake Utsunomiya, Japan A. L. Demain Madison, U.SA. K. L. Rinehart Urbana, U.S.A. A. Dietz Kalamazoo, U.S.A. C. P. Schaffner Piscataway, U.S.A. C. H. Hassall London, U.K. E. Schrinner Frankfurt, Germany Toju Hata Tokyo, Japan T. Takeuchi Tokyo, Japan I. R. Hooper Beaufort, U.S.A. T. Takita Tokyo, Japan K. Isono Tokyo, Japan N. Tanaka Tokyo, Japan S. Kondo Tokyo, Japan G. Tunevall Stockholm, Sweden S. Kuwahara Tokyo, Japan Z. Vanek Prague, Czech J. Lein Seattle, U.S.A. L. C. Vining Halifax, Canada K. Maeda Tokyo, Japan M. J. Weinstein ScotchPlains, U.S.A. L. A. Mitscher Lawrence, U.S.A. EDITORIAL BOARD MEMBERS Australia R. W. Rickards Australian Natl. Univ., Canbera Canada M. G. Bergeron L'Univ. Laval, Saint-Foy J. E. Davies The Univ. British Colunbia, Vancouver J. B. McAlpine Ecopia BioSciences Inc., Quebec J. A. Waitz TerraGen, Vancouver (ret.) G. D. Wright McMaster Univ., Hamilton China Y. -R. Cheng Fujian Inst. Microb., Fuzhou C. -N. Zhang Shanghai Inst. Pharm. Ind., Shanghai Czech M. Flieger Acad. Sci. Czech Republi, Prague France A. J. Bryskier Aventis Pharma, Romainville C. Carbon Hospitalier Bichat-Claude Bernard, Paris P. Courvalin Inst. Pasteur, Paris F. LeGoffic Ecole Nationale Superieure de Chimie de Paris, Paris Germany T. Anke Univ. Kaiserslautern, Kaiserslautern K. Krohn Univ. Paderborn, Paderborn Hungary J. Berdy Inst. Drug Res., Budapest F. J. Sztaricskai Hungarian Acad. ci., Debrecen A. Jeney Semmelweis Med. Univ., Budapest India B. N. Ganguli Univ. Bombay, Bombay A. V. Rama Rao The A V Rama Rao Res. Foundation, Hyderabad Italy G. Beretta Lepetit Res. Center, Gerenzano (ret.) G. Cassinelli G. Ronzoni Res. Inst., Milan F. Cozzi Univ. Milan, Milan G. C. Lancini Biosearch Italia S.p.A., Gerenzano F. Parenti Biosearch Italia S.p.A., Gerenzano E. Perrone Pharmacia, Milan F. Zunino Inst. Nazionale Tumori., Milan Japan H. Aoki Fujisawa Pharm. Co., Ltd., Osaka M. Arai Chemtech Labo., Inc., Tokyo T. Beppu Univ. Tokyo, Tokyo T. Endo Kyoritsu College of Pharmacy, Tokyo Y. Fukagawa EBARA Res. Co., Fujisawa T. Furumai Toyama Prefect. Univ., Toyama S. Hashimoto Fujisawa Pharm., Tsukuba M. Hori Showa College Pharm. Sci., Tokyo S. Horinouchi Univ. Tokyo, Tokyo K. Hotta National Inst. of Infect. Diseases, Tokyo D. Ikeda Inst. Microb. Chem., Tokyo A. Imada Nara Inst. Sci. & Tech., Ikoma M. Ishizuka Inst. Chemother., Numazu K. Kakinuma Tokyo Inst. Tech., Tokyo N. Kojima Meijo Univ., Nagoya K. Komiyama The Kitasato Inst., Tokyo M. Konishi Toho Univ., Chiba T. Murakami Meiji Seika Kaisha, Ltd., Odawara K. Nagai Tokyo Inst. Tech., Yokohama H. Nakano Kyowa Hakko Kogyo Co., Ltd., Tokyo Y. Nishimura Inst. Microb. Chem., Tokyo T. Ogita Sankyo Co., Ltd., Tokyo M. Ohno Genox Res., Kawasaki S. Omura The Kitasato Inst., Tokyo H. Osada RIKEN, Inst. Phys. & Chem. Res., Wako H. Seto Tokyo Univ. Agriculture, Tokyo Y. Takahashi Inst. Microb. Chem., Tokyo H. Tanaka Kitasato Univ., Tokyo K. Tatsuta Waseda Univ., Tokyo F. Tomita Hokkaido Univ., Sapporo H. Tomoda Kitasato Inst., Tokyo S. Tsukagoshi Cancer Chemother. Center, Tokyo Y. Uehara National Inst. Infect. Diseases, Tokyo K. Umezawa Keio Univ., Yokohama H. Yamaguchi Teikyo Univ., Tokyo T. Yoshida Shionogi & Co., Ltd., Osaka Korea I. -D. Yoo KRIBB, Yusong Russia Y. V. Dudnik Russian Acad. Med. Sci., Moscow M. N. Preobrazhenskaya Russian Acad. Med. Sci., Moscow Spain M. Barbacid Univ. Autonoma, Madrid A. Jimenez Univ. Autonoma, Madrid J. -F. Martin Univ. Leon, Leon Sweden O. Sterner Univ. Lund, Lund Switzerland O. Zak Ciba-Geigy AG, Basel (ret.) United Kingdom J. E. Baldwin Univ. Oxford, Oxford I. Chopra Univ. Leeds, Leeds E. Cundliffe Univ. Leicester, Leicester M. Dawson Glaxo Wellcome Med. Res. Centre, Stevenage D. J. D. Hockenhull Univ. Salford, Cumbria L. J. Nisbet Brax Genomics Ltd., Cambridge E. Wellington Univ. Warwick, Coventry D. H. Williams Univ. Cambridge, Cambridge S. K. Wrigley Cubist Pharm., Berkshire U. S. A P. Actor Paul Actor Associates, Phoenixville J. F. Barrett Merck and Co Inc., Rahway M. R. Boyd Univ. South Alabama, Mobile D. E. Cane Brown Univ., Providence G. T. Carter Wyeth-Ayerst Res., New York B. G. Christensen Advanced Medicine Inc., South San Francisco M. Chu Schering-Plough Res. Inst., Kenilworth Ray. Cooper Shaklee Corp., Pleasanton Rob. D. G. Cooper Eli Lilly & Co., Indianapolis (ret.) P. Crews Univ. California, Santa Cruz R. P. Darveau Univ. Washington, Seattle T. W. Doyle VIRON Pharm., New Haven M. N. Dudley Essential Therapeutics, Mountain View P. B. Fernandes Morphochem-SMT, Monmouth Junction A. K. Ganguly Stevens Inst. Tech., Hoboken E. I. Graziani Wyeth-Ayerst Res., Pearl River D. R. Houck Pharmakey, Chapel Hill L. H. Huang Pfizer Inc., Groton C. R. Hutchinson Kosan Biosciences, Inc., Hayward H. A. Kirst Eli Lilly & Co., Indianapolis M. -S. Kuo Pharmacia & Upjohn Inc., Kalamazoo D. P. Labeda National Center Agricultural Utilization Res., Peoria P. A. Lartey Pharmacia & Upjohn Inc., Kalamazoo R. B. Lingham Merck and Co. Inc., Rahway C. -M. Liu Hoffmann-La Roche Inc., Nutley H. Maehr Hoffmann-La Roche Inc., Nutley A. K. Mallams Schering-Plough Corp., Kenilworth E. D. McGruder Eli Lilly & Co., Indianapolis G. H. Miller Essential Therapeutics, Mountain View M. J. Miller Univ. Notre Dame, Notre Dame S. Mobashery Wayne State Univ., Detroit R. L. Monaghan Merck Res. Labo., Rahway R. Nagarajan Eli Lilly & Co., Indianapolis C. H. Nash, III ViroPharma Inc., Annandale R. C. Pandey Xechem Inc., New Brunswick W. L. Parker Bristol-Myers Squibb Co., New Brunswick I. C. Paul Univ. Illinois, Urbana J. J. Plattner Chiron Corp., Emeryville S. F. Queener Indiana Univ. School Med., Indianapolis F. C. Sciavolino Pfizer Global R & D, New London Groton A. B. Smith Univ. Pennsylvania, Philadelphia D. P. Taylor Sunol Molecular Corp., Miramar R. T. Testa Lederle Lab., Pearl River R. C. Thomas Pharmacia & Upjohn Inc., Kalamazoo J. A. Weisbach JAW Associates, Ann Arbor R. J. White Versicor Inc., Fremont T. J. Williams Photogen Tech., Inc., New Hope R. C. Yao Eli Lilly & Co., Indianapolis L. Zhang Cetek, Inc., Lexington Managing Editor M. Yagisawa Japan Antibiotics Research Association, Tokyo